Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion
CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation
Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation
Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones
Inspira Technologies OXY B.H.N. (NASDAQ:IINN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.